Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Auris Medical (EARS)

Auris Medical (EARS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Receives FDA and EMA Guidance for Keyzilen(R) Late-Stage Clinical Development Program

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Appointment of New Chief Financial Officer

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
New Strong Sell Stocks for August 23rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

SHEN : 44.06 (-0.16%)
HAFC : 19.52 (+0.57%)
SSD : 83.38 (-0.75%)
ACY : 4.41 (-3.92%)
EARS : 1.54 (-4.96%)
New Strong Sell Stocks for August 22nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

SBS : 14.37 (+0.35%)
HAFC : 19.52 (+0.57%)
LPL : 6.83 (+1.64%)
ACY : 4.41 (-3.92%)
EARS : 1.54 (-4.96%)
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Closing of Public Offering of Common Shares

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Holding Ltd.:

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Announces Reverse Stock Split

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Research Report Identifies National General, Eidos Therapeutics, Auris Medical Holding AG, and Realogy with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National General Holdings Corp...

NGHC : 22.77 (+0.26%)
EIDX : 55.39 (-0.32%)
EARS : 1.54 (-4.96%)
RLGY : 10.00 (+1.21%)
Auris Medical Provides Update on Tinnitus Drug Development Strategy

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 1.54 (-4.96%)
Auris Medical Receives Positive Nasdaq Listing Determination

EQNX::TICKER_START (NasdaqGM:EARS), EQNX::TICKER_END

EARS : 1.54 (-4.96%)
Auris Medical Announces 20-F Filing

March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system...

EARS : 1.54 (-4.96%)
Auris: 4Q Earnings Snapshot

ZUG, Switzerland (AP) _ Auris Medical Holding AG (EARS) on Thursday reported a loss of $3.7 million in its fourth quarter.

EARS : 1.54 (-4.96%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar